Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Supplemental material
  • Version history
Article has an altmetric score of 2

See more details

Posted by 3 X users
Referenced by 2 Bluesky users
  • Article usage
  • Citations to this article (0)
Advertisement

ResearchIn-Press PreviewImmunologyInflammation Open Access | 10.1172/jci.insight.185581

Regulatory T cells epigenetically reprogrammed from autoreactive effector T cells mitigate established autoimmunity

Tyler R. Colson,1 James J. Cameron,1 Hayley I. Muendlein,2 Mei-An Nolan,1 Jamie L. Leiriao,1 James H. Kim,2 Alexander N. Poltorak,1 and Xudong Li1

1Graduate Program in Immunology, Tufts Graduate School of Biomedical Sciences, Boston, United States of America

2Department of Immunology, Tufts University School of Medicine, Boston, United States of America

Find articles by Colson, T. in: PubMed | Google Scholar

1Graduate Program in Immunology, Tufts Graduate School of Biomedical Sciences, Boston, United States of America

2Department of Immunology, Tufts University School of Medicine, Boston, United States of America

Find articles by Cameron, J. in: PubMed | Google Scholar

1Graduate Program in Immunology, Tufts Graduate School of Biomedical Sciences, Boston, United States of America

2Department of Immunology, Tufts University School of Medicine, Boston, United States of America

Find articles by Muendlein, H. in: PubMed | Google Scholar

1Graduate Program in Immunology, Tufts Graduate School of Biomedical Sciences, Boston, United States of America

2Department of Immunology, Tufts University School of Medicine, Boston, United States of America

Find articles by Nolan, M. in: PubMed | Google Scholar

1Graduate Program in Immunology, Tufts Graduate School of Biomedical Sciences, Boston, United States of America

2Department of Immunology, Tufts University School of Medicine, Boston, United States of America

Find articles by Leiriao, J. in: PubMed | Google Scholar

1Graduate Program in Immunology, Tufts Graduate School of Biomedical Sciences, Boston, United States of America

2Department of Immunology, Tufts University School of Medicine, Boston, United States of America

Find articles by Kim, J. in: PubMed | Google Scholar

1Graduate Program in Immunology, Tufts Graduate School of Biomedical Sciences, Boston, United States of America

2Department of Immunology, Tufts University School of Medicine, Boston, United States of America

Find articles by Poltorak, A. in: PubMed | Google Scholar

1Graduate Program in Immunology, Tufts Graduate School of Biomedical Sciences, Boston, United States of America

2Department of Immunology, Tufts University School of Medicine, Boston, United States of America

Find articles by Li, X. in: PubMed | Google Scholar

Published July 31, 2025 - More info

JCI Insight. https://doi.org/10.1172/jci.insight.185581.
Copyright © 2025, Colson et al. This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
Published July 31, 2025 - Version history
View PDF
Abstract

Reprogramming autoreactive CD4⁺ effector T (Teff) cells into immunosuppressive regulatory T (Treg) cells represents a promising strategy for treating established autoimmune diseases. However, the stability and function of such reprogrammed Tregs under inflammatory conditions remain unclear. Here, we show that epigenetic activation of core Treg identity genes in Teff cells yields lineage-stable Effector T cell Reprogrammed Tregs (ER-Tregs). A single adoptive transfer of ER-Tregs not only prevents autoimmune neuroinflammation in mice when given before disease onset but also arrests its progression when administered after onset. Compared to Foxp3 overexpressing Teff cells, induced Tregs from naïve precursors, and endogenous Tregs, ER Tregs provide superior protection against autoimmune neuroinflammation. This enhanced efficacy stems from their inherited autoantigen specificity and selectively preserved effector cell transcriptional programs, which together bolster their fitness in inflammatory environments and enhance their suppressive capacity. Our results establish epigenetic reprogramming of autoreactive Teff cells as an effective approach to generate potent, stable Tregs for the treatment of refractory autoimmune conditions.

Graphical Abstract
graphical abstract
Supplemental material

View

Version history
  • Version 1 (July 31, 2025): In-Press Preview

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

Article has an altmetric score of 2
  • Article usage
  • Citations to this article (0)

Go to

  • Top
  • Abstract
  • Supplemental material
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts

Posted by 3 X users
Referenced by 2 Bluesky users
See more details